TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03021278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection
Description: In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
Study: NCT04629937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPECT acquisitions
Description: All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
Study: NCT01463228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT01982175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3\~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------
Study: NCT01240252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human insulin
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
Study: NCT01475422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Maps Diabetes Education
Description: The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
Study: NCT03954288

Intervention type: DIAGNOSTIC_TEST
Intervention: serum for sclerostin ELISA test
Description: Blood sample to measure serum sclerostin level

Intervention type: DIAGNOSTIC_TEST
Intervention: serum for sclerostin ELISA test
Description: Blood sample to measure serum sclerostin level

Intervention type: DIAGNOSTIC_TEST
Intervention: serum for sclerostin ELISA test
Description: Blood sample to measure serum sclerostin level
Study: NCT01545557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dermal filler gel
Description: 1 Emervel Volume injection per indication and 1 touch-up injection if necessary
Study: NCT04488042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stapler-less gastrectomy
Description: After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
Study: NCT03214549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gull wing preparation of laminates veneers
Description: preparation involving mesial and distal extension further lingualy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional preparation of laminates veneers
Description: preparation not involving mesial and distal extension further lingualy.
Study: NCT03935334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biosimilar eptacog alfa, activated (AryoSeven)
Description: A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa, activated (Novoseven)
Description: A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
Study: NCT03706976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Oxygenation Monitoring
Description: The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
Study: NCT02949141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: All patients will receive lung ultrasound, chest x-ray and computed tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Description: All patients will receive chest x-ray as per usual care for evaluation for pneumonia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography (CT)
Description: All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
Study: NCT00061750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deferoxamine
Study: NCT03747809

Intervention type: DEVICE
Intervention: CIEDs Remote Monitoring System
Description: Cardiac device remote monitoring system
Study: NCT03434028

Intervention type: DRUG
Group type: OTHER
Intervention: Early Vasopressors
Description: Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met.

Intervention type: OTHER
Group type: OTHER
Intervention: Early Fluids
Description: Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted.
Study: NCT01458847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-UCA solution
Description: Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-UCA solution
Description: Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-UCA solution
Description: Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
Study: NCT02759926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denatonium benzoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denatonium benzoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tap water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Study: NCT00940862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVB Phototherapy
Description: This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical treatment
Description: This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids.
Study: NCT00585078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT00985270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03391856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC)
Description: NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant

Intervention type: OTHER
Group type: OTHER
Intervention: supportive therapy
Description: prophylactic platelet transfusion was given when platelet count \<20000/ul
Study: NCT02438371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Study: NCT00509405

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: potassium citrate
Description: 6 times 10 mEq per day, oral for 24 months
Study: NCT02689947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Study: NCT02781311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant
Description: Setipiprant tablets, orally, BID for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, BID for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride tablet, orally, once daily for 24 weeks.
Study: NCT02788071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: 25 capsules per day for 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FMT placebo
Description: 25 capsules per day for 12 days
Study: NCT01066715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 052
Description: Sterile solution subcutaneously administered monthly for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution subcutaneously administered monthly for 6 months
Study: NCT03764995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard bowel management
Description: Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard bowel management
Description: Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound
Description: Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
Study: NCT00832364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin (also called U0279)
Description: Capsules containing 25 mg U0279 taken once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Injectable Biologic

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Injectable Biologic
Study: NCT04438122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cabernet Sauvignon
Description: Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tsipouro
Description: Tsipouro is a greek spirit which contains 38% alcohol vol
Study: NCT01157351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paliperidone
Description: flexible dosing as prescribed by the study doctor for 15 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: flexible dosing as prescribed by the study doctor for 15 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidole
Description: flexible dosing as prescribed by the study doctor for 15 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perphenazine
Description: flexible dosing as prescribed by the study doctor for 15 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: flexible dosing as prescribed by the study doctor for 15 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: flexible dosing as prescribed by the study doctor for 15 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 78, 117, 156, or 234 mg monthly injection for 15 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: flexible dosing as prescribed by the study doctor for 15 months
Study: NCT00890539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Description: Clinical and research test used in asthma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine challenge
Description: Clinical and research test used in asthma
Study: NCT03527641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CookingMatters
Description: Nutrition education and hands-on cooking lessons for the whole family

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CookingMatters
Description: Nutrition education and hands-on cooking lessons for the whole family

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parenting, physical activity and nutrition education, and family health education for parents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education
Description: Parenting, physical activity and nutrition education, and family health education for parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical fitness activities for teens

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical fitness activities for teens

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health knowledge curriculum for adolescents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: Adolescent mindfulness curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Intervention
Description: Parent-based education and experiential learning of mindfulness-based tools
Study: NCT01988298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg each 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Control group
Study: NCT00814411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group family planning counseling
Description: group family planning counseling for gynecological patients with unmet need

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual family planning counseling
Description: Individual family planning counseling with gynecological patients - the current standard of care
Study: NCT02306447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS and rTMS
Description: rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark).
Study: NCT01050361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)
Description: Duration lasts the entire operation.
Study: NCT04388696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sisterhood 2.0
Description: The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sisterhood 2.0
Description: The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
Study: NCT01672398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring plus self-management support
Description: Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
Study: NCT00523068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tension free vaginal tape
Study: NCT00207402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Infergen 15mcg/ d Avandia qd Ribavirin bid